GM-CSF Fails to Improve Immune Responses to Booster Hepatitis B Vaccination in HIV-Infected Individuals
Edgar T Overton*, 1, Somnuek Sungkanuparph2, Michael Klebert1, Michael Royal1, Debra Demarco-Shaw1, William G Powderly3, Judith A Aberg4
Identifiers and Pagination:Year: 2011
First Page: 109
Last Page: 113
Publisher Id: TOVJ-5-109
Article History:Received Date: 20/5/2011
Revision Received Date: 22/7/2011
Acceptance Date: 1/8/2011
Electronic publication date: 14/10/2011
Collection year: 2011
open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
Hepatitis B (HBV) vaccination is an important preventive intervention for HIV-infected population. Data regarding booster HBV vaccine for persons with low HBV surface antibody (sAb) titers after vaccination in this immunocompromised population is lacking.
We randomized 60 HIV-infected subjects lacking HBV protection after completion of 3 doses of HBV vaccine to receive a booster dose of HBV vaccine with 250mcg GM-CSF as an adjuvant or booster vaccine alone.
GM-CSF was safe with expected side effects. However, only 35% of persons receiving GM-CSF developed protective sAb while 50% in vaccine only arm developed protection (P = 0.47). Overall, only 28% of subjects maintained protective sAb 1 year after vaccination.
GM-CSF failed to improve responses to the booster HBV vaccination. Overall, response was poor with only 42% of persons responding at one month post-vaccination confirming booster vaccination with the current HBV vaccine has poor immunogenicity among HIV-infected persons. Further research is needed to develop optimal vaccination strategies in HIV-infected persons.
Hepatitis B virus (HBV), the leading worldwide cause of chronic liver disease [1,2], shares routes of transmission with Human Immunodeficiency virus (HIV) as manifest by the 30-90% of HIV-infected patients having evidence of prior HBV infection and 10% with chronic infection . In the current era of effective antiretroviral therapy (ART), liver disease among HIV-infected populations is becoming more prominent as AIDS related morbidity and mortality declines [4-8]. Current guidelines recommend HBV vaccination for all HIV-infected persons who do not have evidence of current or past exposure to HBV [9,10].
While vaccination with recombinant HBV vaccine yields durable protection in greater than 90% of vaccinated immunocompetent adults [11,12], HIV-infected persons respond poorly to vaccination with response rates ranging from 17 to 56% with standard HBV vaccination strategies [13-16]. Therefore, current guidelines for the prevention of HBV infection recommend completing a three dose vaccine series with double dose vaccine (40mcg) with subsequent evaluation of HBsAb titers one month after vaccination and annually to assess durable immunity. In immunocompromised persons such as HIV-infected persons, protective immunity persists only while HBsAb ≥10mIU/mL [17,18]. When the antibody level is below this protective level, booster vaccination is recommended .
Given the poor immunogenicity of HBV vaccine in HIV-infected persons, several studies have looked at various strategies, including booster vaccinations and the use of adujvants to boost the immune response. Recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF) is a cytokine produced primarily by activated T and B lymphocytes that has been used extensively as a hematopoietic growth factor. It increases neutrophil count, improves APC function, and is involved in the development and perpetuation of cellular immune responses . GM-CSF has been studied as an adjuvant to HBV vaccination in persons with end stage renal disease and HIV-infected individuals. A meta-analysis of 13 studies evaluating GM-CSF as an adjuvant for HBV vaccine yielded a 50% increase in the development of seroprotection after a single dose of vaccine and a 20% increase after the 3 dose series .
We hypothesized that GM-CSF would serve as an adjuvant to augment the response to a booster dose of HBV vaccine in HIV infected patients who failed the standard 3 dose HBV vaccine series. This approach has proven effective in end stage renal disease patients and dialysis patients, another group of immunocompromised patients [22-24]. This study was developed to evaluate the use of GM-CSF as an adjuvant will augment the response to booster vaccination in a cohort of HIV-infected persons previously vaccinated against HBV.
This study was performed at a single site with 60 participants enrolled. Study participants were HIV-infected volunteers without serologic evidence of prior hepatitis B infection (negative HBV sAg and negative HBV cAb) and who had failed to respond to HBV vaccination, as documented by a HBV surface Ab <10 mIU/mL after completing the 3 dose HBV vaccination series. Participants were required to be ≥18 years of age and to have a current CD4 cell count >100 cells/mL at time of entry. Exclusion criteria included current pregnancy, prisoners, other medical conditions which may be contraindication for receipt of GM-CSF, and anticipated inability to complete the requirements of the study.
The study was approved by the Washington University Human Research Protection Office and written informed consent was obtained from all study participants prior to study initiation. After consent was obtained, participants were stratified based on the level of plasma HIV RNA level into two groups: those with > 400 copies/mL and those with ≤400 copies/mL.
All subjects received a single IM booster dose of 40mcg of recombinant HBV vaccine (Recombivax®) in the deltoid muscle. The subjects randomized to the GM-CSF arm then received an IM dose of 250mcg of GM-CSF (Leukine®) into the same deltoid muscle. Baseline demographic data as well as clinical parameters related to vaccine non-response (age, race, gender, BMI, smoking, HCV status) and HIV parameters were collected at baseline.
The primary endpoints in this study were the quantitative HBV sAb and the seroconversion rates, defined as HBV sAb titer ≥10 mIU/mL 1 month after vaccination. Secondary endpoints included safety and tolerability of the vaccine and GM-CSF, changes in CD4 cell count, and plasma HIV viral load at 1 month, and quantitative HBsAb at 12 months.
Subjects were monitored for 30 minutes after vaccination for adverse reactions and then received a phone call at 48 hours for evaluation of any adverse symptoms. Participants returned at day 7 and day 28 for a targeted physical examination including vital signs, evaluation of the injection site and focusing on any specific signs or symptoms. Laboratory evaluation was performed at day 7 and 28 to monitor changes in blood counts. Participants returned at week 48 for final quantitative HBsAb.
Based on an expected development of HBV sAb ≥ 10mIU/ml of 60% in the GM-CSF arm and 20% in the vaccine only arm, we estimated a sample size of 48. This calculation is based on a two-sided α = 0.05 and a β = 0.10. Based on an assumed 20% drop-out rate, we enrolled a total of 60 participants to the study, 30 participants in each arm. Differences between groups were determined using Student’s t-test for normally distributed continuous variables, Mann-Whitney U test for continuous variables not normally distributed, and Chi squared test for proportions. All analyses were two-tailed and significance was considered if the p-value ≤ 0.05.
Sixty HIV-infected subjects, aged 20-60 years (mean age 37.9 years) were enrolled in the study in 2005 and 2006. The majority of the study participants were African American (72%) and female (58%). Forty two subjects were on ART at study entry with 32 (76%) of those having HV RNA <400 cp/mL. Other baseline parameters are listed in Table 1. All subjects received vaccine or vaccine and GM-CSF and were available for initial safety and tolerability assessment. Four subjects were found to have reactive HBV cAb at day 7 assessment and were excluded from subsequent antibody evaluation, leaving 27 subjects in the vaccine only arm and 29 subjects in the vaccine plus GM-CSF arm. Twenty six participants in each arm completed the 48 week efficacy assessment; in the intervening period, three relocated out of the area and one was lost to follow-up.
Baseline Demographics and Other Factors
|Vaccine Only (n=30)||Vaccine + GM-CSF (n=30)||p-Value|
|Mean Age ± SD (in years)||38.5 ± 10.0||37.3 ± 9.7||0.619|
|AA||23 (76.7%)||20 (66.7%)||0.390|
|Caucasian||7 (23.3%)||10 (33.3%)|
|Female||17 (56.7%)||18 (60%)||0.793|
|Male||13 (43.3%)||12 (40%)|
|Mean BMI ± SD||29.3 ± 7.6||30.3 ± 11.1||0.691|
|Current smoker||11 (36.7%)||10 (33.3%)||0.787|
|Reactive HCV Ab||2 (6.7%)||1 (3.3%)||0.554|
|Mean log10 plasma HIV RNA ± SD||2.7 ± 1.1||3.0 ± 1.2||0.455|
|Plasma HIV RNA||16 (53.3%)||16 (53.3%)||1.0|
|< 400 copies/mL|
|Median Nadir CD4 count (IQR)||162 (71-271)||207 (91-304)||0.429|
|Median CD4 count at enrollment (IQR)||375.5 (290-663)||425 (288-564)||0.865|
|On ART at enrollment||21 (70%)||21 (70%)||1.0|
|Vaccine Only||Vaccine + GM-CSF||p-Value|
|Median 1 month HBsAb||9.4 mIU/mL||0 mIU/mL||NS|
|% with HBsAb > 10mIU/mL||50%||35%||0.47|
|at 1 month||(14/28)||(10/29)|
|Median 1 year HBsAb||0 mIU/mL||0 mIU/mL||NS|
|% with HBsAb > 10mIU/mL||33%||23%||0.71|
|at 1 year||(9/27)||(6/26)|
|Vaccine Only||Vaccine + GM-CSF||p-Value|
|Any adverse event*||4 (13.3%)||17 (56.7%)||<0.001|
|Soreness at injection site||0 (0%)||2 (7.7%)||0.150|
|Redness at injection site||0 (0%)||0 (0%)||1.0|
|Headache||3 (10%)||10 (33.3%)||0.028|
|Fever||3 (10%)||8 (26.7%)||0.095|
|Chest pain||0 (0%)||2 (7.7%)||0.150|
|Dyspnea||1 (3.3%)||1 (3.3%)||1.0|
* Other reported side effects included itching, back pain, leg pain, nausea, dizziness, nasal congestion, and swollen tongue.
All adverse events were grade 1 and resolved within 24 hours.
Responses to booster vaccination were poor for both groups. Overall, only 42% of subjects developed a protective antibody response (HBsAb ≥10mIU/mL). Although there was a trend for more responders in the vaccine only arm (50% vs 35%), the numbers are small and the results are not significant. There was a decrease in antibody responses from 1 month to 1 year in both arms of the study (28% overall). Table 2 shows the immune responses for the two study groups. The development of protective Ab response was not associated with any of the baseline factors including CD4 cell count or level of HIV viremia at time of vaccination.
SAFETY AND SIDE EFFECTS
All subjects received a follow-up phone interview at 48 hours to assess for side effects. Twenty one subjects reported at least one side effect, four in the vaccine only arm and seventeen in the GM-CSF arm (p <0.001). All side effects were mild (grade 1 by the DAIDS toxicity table) and resolved within the first 24 hours after vaccination. No participant had a side effect requiring bed rest, loss of work, or cancellation of social activities. Adverse events are shown in Table 3.
These data illustrate that GM-CSF is safe with expected side effects in HIV-infected subjects when administered as an adjuvant for booster HBV vaccination. Unfortunately, in this study there was no benefit to giving this adjuvant to improve responses in HIV-infected subjects who have failed to respond to the initial series of HBV vaccination. Furthermore, the use of booster vaccination failed to yield protection in a majority of HIV-infected subjects.
In immunocompetent persons, protection from HBV infection remains intact even when HBsAb titers wane <10mIU/mL. Immune memory is preserved and when confronted with HBV sAg (either by exposure to virus or vaccine), a clonal expansion of memory B and T lymphocytes occurs, yielding measurable titers of HbsAb and preventing infection . A recent review by Leuridan and Van Damme compiled data from 13 published studies highlighting a robust anamnestic response to a booster HBV vaccine (62-100%) in HIV negative populations . Furthermore, Bauer et al. illustrated persistent T and B-cell memory in HBV vaccinees with HBsAb titers<10 mIU/mL suggesting that measurable antibodies are not necessary for long term protection . Finally, long term seroprevalence studies in high endemic countries report a marked decrease in incidence of acute HBV and prevalence of chronic HBV carriage since the inception of universal vaccination. Taiwan serves as an excellent example where the HBV carrier rate has declined from 9.8% before universal vaccination to 0.8% 23 years after the commencement of the program [28,29]. The data from these different types of studies (anamnestic responses, residual cellular immunity, and long-term epidemiologic studies) have led to the recommendation that booster vaccination is not necessary among healthy individuals [26,30].
Immunocompromised patients, on the other hand, are at risk for HBV infection when HBsAb titer <10mIU/mL. Data from dialysis patients and HIV-infected persons illustrate that HBsAb titers are significantly lower among immunocompromised patients compared to healthy controls and that the secondary immune response is not as robust [13-19, 31]. Additionally, cases of confirmed HBV infection (HBsAg reactivity) have been reported among HIV-infected persons despite HBV vaccination [32-34]. Therefore, booster vaccine is recommended for persons with immunocompromised states. Unfortunately, booster vaccine generally fails to yield protection in a large proportion of subjects. Our findings of 42% response in HIV-infected adults are similar to those recently reported in an ACTG pediatric study in which 46% of HIV-infected children developed protective immunity after a booster dose of HBV vaccine . How do we enhance immune responses on these at risk populations?
Improving the response in immunocompromised patients remains challenging. While the initiation of HAART with subsequent increase in CD4 cell count and reduction in HIV viral load has been associated with improved vaccine responses in children and adolescents, the rates of response remain below that reported in healthy individuals . The utility of alternative strategies, specifically alternative adjuvants are one mechanism to augment the response. In this study, we elected to evaluate GM-CSF as an adjuvant given previous data suggesting its utility for vaccine responses in both dialysis patients and HIV-infected persons [21-23,36]. Unfortunately, the current study failed to find similar benefit with GM-CSF. Rather, the findings are similar to results recently published which evaluate the use of GM-CSF as an adjuvant for primary HBV vaccine series in HIV-infected persons . One question is whether the difference in dosing strategies used in these studies accounts for the differences in responses reported or if there are factors related to the different populations, such as nadir or current CD4 cell counts, which may impact response.
Nevertheless, these data leave clinicians unclear of the appropriate management of vaccine non-responders and individuals with waning antibody titers. In HIV-infected individuals, the underlying cause for the poor and transient response remains intriguing. The altered immune system prevents the propagation of an appropriate memory response even among those on suppressive ART therapy. Additional research is needed to inform the best approach.
Our study is limited by a relatively small sample size. It is also limited by the fact that we cannot differentiate participants who were non-responders to the initial vaccine series versus those who responded but had waning HBsAb titer. This latter fact may be important as those who initially respond may be good candidates for booster vaccination rather than require a repeat of the three dose vaccination series. The time from receipt of the initial vaccine series and the booster dose was highly variable which also may impact the response to a booster vaccination.
The results from our study confirm that a single booster vaccine is unlikely to yield significant immune protection against HBV for the HIV-infected population. The alternative strategy of repeating the three dose vaccine series is an alternative strategy that may yield better results. The addition of GM-CSF as an adjuvant, an approach that has shown promise in other studies and in other immunocompromised populations, failed to improve responses in the present study. Continued efforts must strive to identify a more effective strategy for HBV vaccination in HIV-infected persons.
AUTHOR DISCLOSURE STATEMENT
No competing financial interests exist.